Facebook
Twitter
LinkedIn
ForwardWebinar: Incredible Incretins: Applying the Evidence Behind GIPs and GLP-1s
Given the wide-ranging benefits seen with incretin-based therapies, modulating the release of endogenous gut hormones, such as GIP and GLP-1, through dietary modification may be a promising approach for the treatment of obesity and type 2 diabetes, especially when combined with synthetic incretin analogues (GLP-1RAs). Furthermore, the use of endogenous incretins has the advantage of mitigating the known GLP-1 medication side effects, as well as stimulating the release of other appetite suppressing hormones. However, a current understanding of the cellular mechanisms underlying intestinal hormone secretion is critical.
Incretins have been shown to influence the reward center of the brain and mitigate the desire to consume food simply for pleasure (hedonic response). Thus, an understanding of the biology of homeostatic and non-homeostatic weight loss is necessary. Knowledge of the latest clinical trial data, new GLP-1 s on the market as well as those in the pipeline, patient selection criteria, dosing guidelines and more, is essential when care team members are counseling patients on the use of incretin therapy for weight loss and metabolic disease management.
Join Om Ganda, MD, MACE, and Sangeeta Pradhan, M.Ed, RD, LDN, CDCES, on Wednesday, November 5, 2025, from 2-3:30 p.m. ET, for a webinar that will discuss the efficacy of incretin-based therapies, the long-term outlook including several unanswered questions, and explore the indispensable role diet plays in enhancing endogenous GLP-1 production. Care team members will gain a comprehensive toolkit that will help them collaborate and integrate carefully selected diets and incretin-based therapies. By working together and understanding the science, practitioners will be able to support patients who seek a more sustainable, longer lasting, and more efficacious outcomes when managing weight, blood glucose levels, metabolic disorders, and other clinical endpoints.
Learning Objectives
After completing this continuing education activity, health care professionals will better be able to:
- Explain the mechanism of action and the activation of GIPs, GLP-1s, and GLP-1RAs.
- Review the biology of weight loss and how incretin hormones modify the hedonic response to food.
- Describe the pathways by which certain diets and specific nutrients promote the endogenous release of GLP-1s.
- Strategize how to integrate MNT and GLP-1RAs to produce more efficacious and sustainable outcomes for patients struggling with overweight/obesity and metabolic conditions.
- Discuss each care team member’s unique role and the positive health outcomes that result from collaborative treatment approaches and nutrition education.
Additional Information
Om Ganda, MD, MACE, began his tenure at the Joslin Diabetes Center and the Harvard Medical School as a Research Fellow in 1973. He was Director of Lipid Center, Chair of the Joslin Clinical Guidelines Committee, senior faculty of Global Education and Care (GEC), and is Associate Professor of Medicine at the Harvard Medical School in Boston, MA.
Dr. Ganda has been a co-investigator in a number of NIH-funded clinical trials, including the landmark DCCT/EDIC, and Diabetes Prevention Program (DPP), and several clinical trials related to lipids and cardiovascular disease, including the recently completed REDUCE-IT, and the PROMINENT trials. Earlier, he was a co-investigator in other NIH- sponsored studies on the pathogenesis of diabetes in monozygotic twins and offspring of both parents with type 2 diabetes.
Dr. Ganda is board certified by the American Board of Internal Medicine, American Board of Endocrinology, and American Board of Clinical Nutrition, and he’s an active member of ADA, the Endocrine Society (TES), the American Association of Clinical Endocrinology (AACE), and the National Lipid Association (NLA). He served as a member of the Board of Directors of AACE and a member of the AACE clinical practice and lipid guidelines task force.
As an educator, Dr. Ganda is a frequently invited speaker at various conferences globally. He has over 200 peer-reviewed publications, most in high impact journals, including more than 150 original publications, and has written over 30 book chapters.
Sangeeta Pradhan, M.Ed, RD, LDN, CDCES, works as the Diabetes Program Coordinator of Charles River Medical Associates, a physician practice group in MetroWest, MA. She is the immediate past President of the Massachusetts Academy of Nutrition and Dietetics (MAND) and past President of the Central Massachusetts Dietetic Association. Sangeeta is a sought-after professional speaker and presents on various topics for professional and community organizations, including the state level annual conference of MAND for the last several years. In recognition of her work, Sangeeta was nominated in the top 20 women of the year in 2016 by India New England News.
Sangeeta has presented webinars and podcasts that discuss current and trending dietetics topics and as a South Asian nutrition expert, she’s actively involved in providing nutrition education talks and webinars for the Greater Boston Indian community. As an avid cook and recipe developer, she’s been published in the online and print versions of Food and Nutrition Magazine. Sangeeta’s mission in life is to get the facts pertaining to nutrition to the common consumer without the hype, and to this end, she writes on her nutrition and food blog, Web Dietitian, and can be found on LinkedIn and Instagram @web_dietitian.
Disclosures:
Om Ganda, MD, MACE, faculty for this educational event, has the following relevant financial relationships with ineligible companies to disclose: he is on the Data Monitoring Board for Arrowhead Research and is a consultant for Amarin Pharma. All relevant financial relationships listed for this individual have been mitigated.
Sangeeta Prahdan, M.Ed, RD, LND, CDCES, faculty, and the planners for this educational activity have no relevant financial relationship(s) with ineligible companies to disclose.
An “ineligible company” includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products use by or on patients.
In support of improving patient care, Great Valley Publishing Company is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity will also award credit for dietetics (CDR CPEU).
This activity will also award credit for dietetics (CDR CPEU).
Dietitians:
This activity will also award 1.5 CDR CPEU credits for dietetics. Completion of this RD/DTR profession specific or IPCE activity awards CPEUs (One IPCE credit = One CPEU). If the activity is dietetics-related but not targeted to RDs or DTRs, CPEUs may be claimed which are commensurate with participation in contact hours (One 60-minute hour = 1 CPEU).
RDs and DTRs are to select activity type 102 in their Activity Log. Sphere and Competency selection is at the learner's discretion.
Physicians:
Great Valley Publishing designates this live material for a maximum of 1.5 AMA PRA Category 1 Credit (s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Interprofessional:
This activity was planned by and for the healthcare team, and learners will receive 1.5 IPCE credits for learning and change.
Available Credit
- 1.50 Interprofessional Continuing Education (IPCE)This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credits for learning and change.
Price
Required Hardware/software
Ensure your browser's cookies are enabled in order for the webinar software to function properly.